Celgene (NASDAQ:CELG) is one of biotechnology's brightest shining stars. The company markets a slate of therapies, including its mega blockbuster multiple myeloma drug Revlimid, its fast-growing cancer drug Abraxane, and its newly launched autoimmune drug, Otezla.
Despite Celgene's growing product lineup, shares are trading lower following the company's second quarter earnings report. As a result, investors are right to wonder if Celgene's winning streak is coming to an end.
In the following slideshow, you'll learn which of Celgene's drugs grew fastest and gain insight into whether shares are worth buying.